Patents Assigned to Amgen
  • Sitosterolemia susceptibility gene (SSG): compositions and methods of use
    Patent number: 7662376
    Abstract: The present invention provides nucleic acids encoding a novel ABC family cholesterol transporter, SSG. The herein-disclosed sequences can be used for any of a number of purposes, including for the diagnosis and treatment of cholesterol-associated disorders, including sitosterolemia, and for the identification of molecules that associate with and/or modulate the activity of SSG.
    Type: Grant
    Filed: December 27, 2006
    Date of Patent: February 16, 2010
    Assignee: Amgen Inc.
    Inventors: Hui Tian, Joshua Schultz, Bei Shan
  • 1,2,3,4-tetrahydropyrazin-2-yl acetamides and methods of use
    Patent number: 7662811
    Abstract: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: February 16, 2010
    Assignee: Amgen Inc.
    Inventors: Benny C. Askew, Jr., Toshihiro Aya, Kaustav Biswas, Guolin Cai, Jian J. Chen, Nianhe Han, Qingyian Liu, Thomas Nguyen, Nobuko Nishimura, Rana Nomak, Tanya Peterkin, Wenyuan Qian, Kevin Yang, Chester Chenguang Yuan, Jiawang Zhu, Derin C. D'Amico, Jason B. Human, Qi Huang
  • Polishing steps used in multi-step protein purification processes
    Patent number: 7662930
    Abstract: Various embodiments of the present invention are directed to multi-step systems and methods for target-molecule purification that employ column-chromatography-based and/or membrane-filtration-based polishing steps. In one described embodiment of the present invention, a target-protein-containing eluate having a high residual salt concentration is collected from a first chromatography column prepared with an affinity-chromatography resin, loaded onto a second chromatography column prepared with a cation-exchange resin, and eluted from the second cation-exchange column using a buffer in which a time-dependent pH gradient is established. In another described embodiment of the present invention, a partially purified target-protein-containing eluate is collected from a chromatography column and further purified by passing the target-protein-containing eluate through a salt-tolerant anion exchanger.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: February 16, 2010
    Assignee: AMGEN Inc.
    Inventor: Joe Xin Hua Zhou
  • Modified Fc molecules
    Patent number: 7662931
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: February 16, 2010
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • N-terminally chemically modified protein compositions and methods
    Patent number: 7662933
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.
    Type: Grant
    Filed: April 26, 2006
    Date of Patent: February 16, 2010
    Assignee: Amgen Inc.
    Inventors: Olaf B. Kinstler, Nancy Elise Gabriel, Christine E. Farrar, Randolph B. DePrince
  • ANTIBODY-BASED DIAGNOSTICS AND THERAPEUTICS
    Publication number: 20100036091
    Abstract: Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided.
    Type: Application
    Filed: November 9, 2007
    Publication date: February 11, 2010
    Applicants: AMGEN INC., UCB PHARMA S.A.
    Inventors: Martyn Kim Robinson, Christopher J. Paszty, Alastair James Henry, Alistair Lawson, Andy Popplewell
  • Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
    Publication number: 20100034818
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Application
    Filed: October 9, 2009
    Publication date: February 11, 2010
    Applicants: AMGEN, INC., MEDAREX, INC.
    Inventors: Kenneth D. Wild, JR., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Melanin concentrating hormone receptor antagonist
    Patent number: 7659276
    Abstract: Novel compounds, or pharmaceutically-acceptable salts, tautomers or prodrugs thereof, of Formula I wherein A, W, X, Z, R1-R3, and R8 are as defined in the specification, are provided. Also provided are methods of treating or preventing a melanin concentrating hormone-mediated disorder in a subject, comprising administering to a subject in need of such treatment or prevention a compound of Formula I.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: February 9, 2010
    Assignee: Amgen, Inc.
    Inventors: Christopher Hulme, Paul Tempest, Vu Ma, Thomas Nixey, Guity Balow
  • Benzamide derivatives and uses related thereto
    Patent number: 7659287
    Abstract: Benzamide derivatives of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: February 9, 2010
    Assignee: Amgen Inc.
    Inventors: Jay P. Powers, Yosup Rew, Xuelei Yan
  • Angiopoietin-2 specific binding agents
    Patent number: 7658924
    Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: February 9, 2010
    Assignee: Amgen Inc.
    Inventors: Jonathan Oliner, Kevin Graham
  • REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION
    Publication number: 20100028906
    Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.
    Type: Application
    Filed: October 12, 2009
    Publication date: February 4, 2010
    Applicant: AMGEN FREMONT INC.
    Inventors: Sirid-Aimee Kellermann, Larry L. Green, Wouter Korver
  • Fibroblast Growth Factor-Like Polypeptides
    Publication number: 20100028349
    Abstract: The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.
    Type: Application
    Filed: November 13, 2008
    Publication date: February 4, 2010
    Applicant: AMGEN INC.
    Inventors: Arlen Thomason, Benxian Liu, Dimitry Michael Danilenko
  • S1P1 receptor agonists and use thereof
    Publication number: 20100029611
    Abstract: The present invention relates to compounds of Formula (I): that are have activity as S1P receptor modulating agents, more specifically to specifically compounds that are S1P1 receptor agonists. The invention also related to the use of such compounds to treat diseases associated with inappropriate S1P1 receptor activity such as autoimmune diseases.
    Type: Application
    Filed: June 18, 2009
    Publication date: February 4, 2010
    Applicant: Amgen Inc.
    Inventors: Victor J. Cee, Michael J. Frohn, Brian Alan Lanman, Susana C. Neira, Anthony B. Reed, Kelvin K.C. Sham
  • IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS
    Publication number: 20100028345
    Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
    Type: Application
    Filed: October 1, 2007
    Publication date: February 4, 2010
    Applicant: AMGEN INC.
    Inventors: Joel Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
  • Modified Fc molecules
    Patent number: 7655765
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: February 2, 2010
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • Modified Fc molecules
    Patent number: 7655764
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: February 2, 2010
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • Antagonists of Interleukin-15
    Publication number: 20100015723
    Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R?-subunit and that are incapable of transducing a signal through either the ?- or ?-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the ?- or ?-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
    Type: Application
    Filed: May 23, 2007
    Publication date: January 21, 2010
    Applicants: Amgen Inc., IMMUNEX CORPORATION
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
    Patent number: 7649110
    Abstract: The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formula Q—L1—P—L2—M—X—L3—A wherein the definitions of the variables Q, L1, P, L2, M, X, L3 and A are provided herein. The present invention also provides compositions and methods for use of the compounds, for instance, for treatment of type II diabetes.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: January 19, 2010
    Assignee: Amgen Inc.
    Inventors: Michelle Akerman, Jonathan Houze, Daniel C. H. Lin, Jinqian Liu, Jiwen Liu, Jian Luo, Zhihua Ma, Julio C. Medina, Wei Qiu, Jeffrey D. Reagan, Rajiv Sharma, Michael J. Schmitt, Stephen J. Shuttleworth, Ying Sun, Yingcai Wang, Jian Zhang, Liusheng Zhu
  • Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
    Publication number: 20100010201
    Abstract: The present invention relates in general to metalloproteinase inhibitors and to polynucleotides encoding such inhibitors. In particular, the invention relates to novel mammalian inhibitors of metalloproteinase, which are designated as type three or TIMP-3, to fragments, derivatives, and analogs thereof, and to polynucleotides encoding the same. Novel methods of producing such compositions and novel methods of using such compositions are also provided.
    Type: Application
    Filed: September 18, 2008
    Publication date: January 14, 2010
    Applicant: Amgen Inc.
    Inventors: Scott M. Silbiger, Raymond A. Koski
  • AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE
    Publication number: 20100010014
    Abstract: The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.
    Type: Application
    Filed: September 18, 2009
    Publication date: January 14, 2010
    Applicant: Amgen Inc.
    Inventors: Adrian Leonard Smith, Paul Edward Brennan, Frenel Fils DeMorin, Gang Lin, Nick A. Paras, Daniel Martin Retz, Elizabeth Rainbeau